Sleep disruption affects up to 85% of children with cerebral palsy, creating cascading health problems and family stress that conventional behavioral interventions often fail to address. This finding offers families a evidence-based pharmaceutical option when sleep hygiene approaches prove insufficient.
A 12-week randomized controlled trial involving 120 children with cerebral palsy found that escalating melatonin doses (3-10mg daily) produced clinically meaningful sleep improvements. By study completion, children receiving melatonin fell asleep nearly 28 minutes faster than placebo recipients and gained an additional 1.3 hours of total sleep nightly. The sleep onset improvements emerged gradually, reaching 9 minutes at 4 weeks before expanding to the full 28-minute reduction. Only 10 participants experienced mild side effects.
For neurologically compromised children, sleep disturbances often stem from disrupted circadian rhythms rather than behavioral factors alone, making melatonin's chronobiological effects particularly relevant. The hormone's ability to synchronize internal clocks may prove especially valuable in cerebral palsy, where brain injury frequently disrupts normal sleep-wake cycling. However, this pediatric population represents a specific neurological context, and the optimal dosing strategy—starting at 3mg and escalating to 10mg—may not translate directly to typical childhood insomnia or adult applications. The study's 12-week duration also leaves questions about long-term efficacy and tolerance. While promising for families managing cerebral palsy-related sleep challenges, these results require replication across broader pediatric populations and longer observation periods to establish melatonin's role in mainstream pediatric sleep medicine.